“showed a trend”

Left STR and left SFG also showed a trend toward sensitivity to Factor 1 [1-tailed t (15) = 1.13, p = 0.14 and 1-tailed t (15) = 1.16, p = 0.13, respectively].

Denosumab also showed a trend of delayed time to first and subsequent SREs over zoledronic acid [rate ratio = 0.90; 95% CI 0.77–1.04; P = 0.14 (superiority)].

Amplitudes at this latency for correct and incorrect trials were reliably different for the II distribution ( F (1,11) = 6.3, p = 0.03, η p 2 = 0.37) and showed a trend in the opposite direction for the RB distribution ( F (1,11) = 2.6, p = 0.14, η p 2 = 0.19).

Outcome analysis in the whole cohort (Table 2 ) showed a trend towards a reduction of stage 2–3 AKI in the HOPE group (87 [32.3%] versus 4 [16%]; p = 0.140).

For the landmark task, both groups only showed a trend toward a significant rightward deviation from the midpoint of the line [TAPAT Group: t (1,11) = 1.57, p > 0.14; Control Group: t (1,10) = 1.88, p > 0.09], likely due to the greater variability among subjects in this task.

The statistical analysis showed a trend ( t -test, p = 0.14) toward a larger amplitude ratio R in gray matter in patients compared with healthy controls (Figure 13 C).

Clostridium butyricum MIYAIRI, in a separate randomized trial of 17 patients, showed a trend toward less acute pouchitis compared to placebo (11 vs. 50% P = 0.14) over a period of 24 months ( 40 ).

Non-GDM mothers with BMI <25 showed a trend for higher I-FABP level (r=-0.35; p=0.14). 3.2.

Mechanical ventilation The aggregation of six RCTs [ 15 , 16 , 62 - 65 ] on FO-containing LEs in which the researchers reported on MV showed a trend toward reduction in the number of days on MV (WMD, −1.14; 95% CI, −2.67 to 0.38; P = 0.14; heterogeneity I 2 = 0%) (see Figure 4 ).

20 showed a trend to a longer fluoroscopy time when using the novel ablation system (14.0 vs. 10.8 min; P = 0.141).

Indeed, RT-PCR analyses of the mRNA of cultured embryos at E9 that had been exposed to glucose for only 7 h showed a trend, albeit not one that was significant ( Daam1 expression P =0.142; Vangl2 expression P =0.086), towards weaker Daam1 and Vangl2 expression.

Higher comorbidity burden showed a trend toward longer hospital stay but was not associated with mortality (aOR = 2.9, 95% CI: 0.70–11.76, p = 0.142; IPW logit with an ATE = +0.016, 95% CI: −0.03–0.06, p = 0.482).

CEUS to absolute dose applied (per cycle 1; Supplementary Tables S2 and S4 ) showed a trend (correlation coefficient r = 0.498, p = 0.142), and DCE-MRI VVF measurements showed a significant correlation with absolute dose applied per cycle 1 (r = 0.556, p = 0.038) but not with dose level per m 2 , whereas k-trans measurements only showed trends.

AD Resilient rats also showed a trend toward fewer inhibitory neurons diverging to two to five inhibitory targets compared with AD Impaired rats ( p = 0.142; Figure 7J ).

When these cases are excluded from survival analyses, median survival was not significantly different, but still showed a trend in favor of the non-AC group, with a median survival of 105 months for AC patients and 136 months for non-AC patients ( p = 0.142).

This showed a trend toward CST IV/V in mid/late menopause compared to early (65.9% vs. 41.2%, p =0.142).

Similarly, the incidence of SFSS in the current policy group also showed a trend toward being lower than in the previous policy group (25.0% vs 55.2%, P =0.143).

While the age group distribution showed a trend toward higher medical use among the 65+ cohort (62.3%), this did not reach statistical significance in the bivariate analysis ( p = 0.143).

Furthermore, subgroup analysis showed a trend towards a benefit of D2 dissection in patients with locally advanced gastric cancer > T1 (DSS 55% for D1 vs. 69% for D2 with p = 0.143) and in N + patients (OS rate of 35% for D1 vs. 51% for D2 and DSS rate of 38% for D1 vs. 59% for D2) and in patients with T2-T4 and N+.

The overall rate of death showed a trend of reduction of 36% (RR [CI] = 0.64 [0.35, 1.16], p = 0.143) in the MSC treatment group.

Patients with any positive autoimmune antibody (anti-SOX2, anti-Hu, anti-Yo, anti-VGCCA, anti-VGPCA, anti-nuclear, anti-neutrophil cytoplasmic antibodies) showed a trend for a prolonged survival (18.5 versus 17 months, p = 0.144), a significantly longer median progression free survival (8.8 versus 7.3 months, p = 0.036) and a trend for a higher response rate ( p = 0.066) [ 85 ].

1.0 ± 0.2, p = 0.046), and SDHA expression showed a trend for higher expression (2.5 ± 0.6 vs. 1.6 ± 0.3, p = 0.144). 3.6.

The Cox proportional hazard regression analyses showed a trend of survival benefit of MetS after adjustment of age, diabetes mellitus, serum levels of total cholesterol, and triglyceride (HR: 0.71, 95% CI: 0.45-1.12, P=0.144) ( Figure 1 ).

More stroma showed a trend of being related to poor DFS in stage II (HR 2.07; 95% CI 0.76–5.60; Log-rank p = 0.144, Additional file 3 : Figure S1a).

Comparing the VF-14 scores of late onset-LHON patients with symptomatic carriers with onset <50 years showed a trend to lower scores for the older patients (18.06+/−15.27 versus 25.14+/−21.18, p = 0.144).